Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Pharmacodynamy and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Crit Rev Oncol Hematol. 2018 Dec;132:145-153. doi: 10.1016/j.critrevonc.2018.09.017. Epub 2018 Oct 4.
The main obstacles that lead to clinical failure in cancer treatment are the development of resistant to chemotherapy and a rise in invasive characteristics in cancer tumor cells due to prolonged chemotherapeutic processes. Recent studies have revealed some evidence about the existence of a direct relationship between development of drug resistance and triggering of invasive capability in tumor cells. Therefore, devising and application of chemotherapeutic procedures that are not prone to the development of chemotherapy resistance are necessary. Here, we focus on CD147, CD44, ANAX2, P-gp, MMPs, and UCH-L1 proteins involved in the crosstalk between metastasis and cancer treatment. We think that further structural and functional analysis of these proteins may direct scientists towards designing highly effective chemotherapy procedures.
导致癌症治疗临床失败的主要障碍是由于化疗过程延长，癌症肿瘤细胞对化疗的耐药性发展和侵袭特性的提高。最近的研究揭示了一些证据，表明药物耐药性的发展与肿瘤细胞侵袭能力的触发之间存在直接关系。因此，设计和应用不易产生化疗耐药性的化疗程序是必要的。在这里，我们重点介绍了 CD147、CD44、ANAX2、P-gp、MMPs 和 UCH-L1 等蛋白在转移和癌症治疗之间的串扰中所起的作用。我们认为，对这些蛋白的进一步结构和功能分析可能会引导科学家设计出更有效的化疗程序。
